Blockade of N-acetylaspartylglutamate peptidases: A novel protective strategy for brain injuries and neurological disorders

International Journal of Neuroscience

Volumn 124, Issue 12, 2014, Pages 867-873

  Zhong, Chunlong ^a   Luo, Qizhong ^a   Jiang, Jiyao ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Brain injury; Glutamate excitotoxicity; N acetylaspartylglutamate (NAAG); Neurological disorder; Neuroprotection

Indexed keywords

GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II INHIBITOR; GLUTAMIC ACID; PHENCYCLIDINE; PHOSPHONIC ACID DERIVATIVE; THIOL DERIVATIVE; UREA DERIVATIVE; ENZYME INHIBITOR; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 3; NEUROPROTECTIVE AGENT;

AMYOTROPHIC LATERAL SCLEROSIS; BRAIN INJURY; BRAIN PROTECTION; DIABETIC NEUROPATHY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; EXCITOTOXICITY; HUMAN; INFLAMMATORY PAIN; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; REVIEW; SCHIZOPHRENIA; TRAUMATIC BRAIN INJURY; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN INJURIES; ENZYMOLOGY; METABOLISM; NERVOUS SYSTEM DISEASES;

ANIMALS; BRAIN INJURIES; ENZYME INHIBITORS; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; NERVOUS SYSTEM DISEASES; NEUROPROTECTIVE AGENTS; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 84909961766     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2014.890935     Document Type: Review

References (86)

1. Conn PJ. Physiological roles and therapeutic potential of metabotropic glutamate receptors. Ann NY Acad Sci 2003; 1003:12-21.
2. Whelan J. NAALADase inhibitors: a novel approach to glutamate regulation. Drug Discov Today 2000;5:171-2.
3. Muir K, Grosset D. Neuroprotection for acute stroke: making clinical trials work. Stroke 1999;30:180-2.
4. Waxman EA, Lynch DR. N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neuroscientist 2005;11:37-49.
5. Faden AI, Demediuk P, Panter SS, et al. The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 1989;244:798-800.
6. Katayama Y, Becker DP, Tamura T, et al. Massive increases in extracellular potassium and the indiscriminate release of glutamate following concussive brain injury. J Neurosurg 1990;73:889-900.
7. Carlton SM, Hargett GL, Coggeshall RE. Localization of metabotropic glutamate receptors 2/3 on primary afferent axons in the rat. Neuroscience 2001;105:957-69.
8. Neugebauer V. Metabotropic glutamate receptors-important modulators of nociception and pain behavior. Pain 2002; 98:1-8.
9. Berent-Spillson A, Robinson AM, Golovoy D, et al. Protection against glucose-induced neuronal death by NAAG and GCP II inhibition is regulated bymGluR3. JNeurochem 2004;89:90-9.
10. Tomiyama M, Furusawa K, Kamijo M, et al. Upregulation of mRNAs coding for AMPA and NMDA receptor subunits and metabotropic glutamate receptors in the dorsal horn of the spinal cord in a rat model of diabetes mellitus. Brain Res Mol Brain Res 2005;136:275-81.
11. Rothstein JD. Of mice and men: reconciling preclinical ALS mouse studies and human clinical trials. Ann Neurol 2003;53:423-6.
12. Strong MJ. Amyotrophic lateral sclerosis: contemporary concepts in etiopathogenesis and pharmacotherapy. Expert Opin Investig Drugs 2004;13:1593-614.
13. Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 2002;42:165-79.
14. Javitt DC, Coyle JT. Decoding schizophrenia. Sci Am 2004;290:48-55.
15. Bullock R, Lyeth BG, Muizelaar JP. Current status of neuroprotection trials for traumatic brain injury: lessons from animal models and clinical studies. Neurosurgery 1999;45:207-17.
16. Narayan RK, Michel ME, Ansell B, et al. Clinical trials in head injury. J. Neurotrauma 2002;19:503-57.
17. Neale JH, Bzdega T, Wroblewska B. N-Acetylaspartyl glutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. J Neurochem 2000; 75:443-52.
18. Neale JH, Olszewski RT, Gehl LM, et al. The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. Trends Pharmacol Sci 2005;26:477-84.
19. Zhou J, Neale JH, Pomper MG, et al. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov 2005;4:1015-26.
20. Barinka C, Rojas C, Slusher B, et al. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem 2012;19:856-70.
21. Durand D, Carniglia L, Caruso C, et al. mGlu3 receptor and astrocytes: partners in neuroprotection. Neuropharmacology. 2013;66:1-11.
22. Coyle JT. The nagging question of the function of Nacetylaspartylglutamate. Neurobiol Dis 1997;4:231-8.
23. Neale JH, Olszewski RT, Zuo D, et al. Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family. J Neurochem, 2011;118:490-8.
24. Wroblewska B, Wroblewski JT, Saab OH, et al. Nacetylaspartylglutamate inhibits forskolin-stimulated cyclic AMP levels via a metabotropic glutamate receptor in cultured cerebellar granule cells. J Neurochem 1993;61:943-8.
25. Wroblewska B, Wroblewski JT, Pshenichkin S, et al. Nacetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells, J Neurochem 1997;69:174-81.
26. Wroblewska B, SantiMR, Neale JH. N-acetylaspartylglutamate activates cyclic AMP-coupledmetabotropic glutamate receptors in cerebellar astrocytes. Glia 1998;24:172-9.
27. Cartmell J, Schoepp DD. Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 2000;75:889-907.
28. Bruno V, Battaglia G, Copani A, et al. Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J Cereb Blood Flow Metab 2001;21:1013-33.
29. Schweitzer C, Kratzeisen C, Adam G, et al. Characterization of -LY354740 binding to rat mGlu2 and mGlu3 receptors expressed in CHO cells using Semliki Forest virus vectors. Neuropharmacology 2000;39:1700-6.
30. Bischofberger J, Schild D. Glutamate and Nacetylaspartylglutamate block HVA calcium currents in frog olfactory bulb interneurons via an mGluR2/3-like receptor. J Neurophysiol 1996;76:2089-92.
31. Zhao J, Ramadan E, Cappiello M, et al. NAAG inhibits KClinduced [(3)H]-GABA release via mGluR3, cAMP, PKA and L-type calcium conductance. Eur J Neurosci 2001;13:340-6.
32. Xi ZX, Baker DA, Shen H, et al. Group II metabotropic glutamate receptors modulate extracellular glutamate in the nucleus accumbens. J Pharmacol Exp Therap 2002;300:162-71
33. Garrido Sanabria ER, Wozniak KM, Slusher BS, et al. GCP II (NAALADase) inhibition suppresses mossy fiber-CA3 synaptic neurotransmission by a presynaptic mechanism. J Neurophysiol 2004;91:182-93.
34. Luthi-Carter R, Berger UV, Barczak AK, et al. Isolation and expression of a rat brain cDNA encoding glutamate carboxypeptidase II. Proc Natl Acad Sci USA 1998;95:3215-20.
35. Bzdega T, Crowe SL, Ramadan ER, et al. The cloning and characterization of a second brain enzyme with NAAG peptidase activity. J Neurochem 2004;89:627-35.
36. Hlouchova K, Barinka C, Klusak V, et al. Biochemical characterization of human glutamate carboxypeptidase III. J Neurochem 2007;101:682-96.
37. Bacich DJ, Ramadan E, OKeefe DS, et al. Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N-acetylaspartylglutamate. J Neurochem 2002;83:20-9.
38. Jackson PF, Cole DC, Slusher BS, et al. Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated-α-linked acidic dipeptidase. J Med Chem 1996;39:619-22.
39. Majer P, Jackson PF, Delahanty G, et al. Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem 2003;46:1989-96.
40. Kozikowski AP, Nan F, Conti P, et al. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J Med Chem 2001;44:298-301.
41. Tsukamoto T, Wozniak KM, Slusher BS. Progress in the discovery and development of glutamate carboxypeptidase II inhibitors. Drug Discov Today 2007;12:767-76.
42. Slusher BS, Vornov JJ, Thomas AG, et al. Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat Med 1999;5:1396-402.
43. Jackson PF, Slusher BS. Design of NAALADase inhibitors: a novel neuroprotective strategy. Curr Med Chem 2001;8:949-57.
44. Tsukamoto T, Flanary JM, Rojas C, et al. Phosphonate and phosphinate analogues of N-acylated-glutamylglutamate: potent inhibitors of glutamate carboxypeptidase II. Bioorg Med Chem Lett 2002;12:2189-92.
45. Oliver AJ, Wiest O, Helquist P, et al. Conformational and SAR analysis of NAALADase and PSMA inhibitors. Bioorg Med Chem 2003;11:4455-61.
46. Maung J, Mallari JP, Girtsman TA, et al. Probing for a hydrophobic a binding register in prostate-speci. c membrane antigen with phenylalkylphosphonamidates. Bioorg Med Chem 2004;12:4969-79.
47. van der Post JP, de Visser SJ, de Kam ML, et al. The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693. Br J Clin Pharmacol 2005;60:128-36.
48. Grella B, Adams J, Berry JF, et al. The discovery and structure-activity relationships of indole-based inhibitors of glutamate carboxypeptidase II. Bioorg Med Chem Lett, 2010;20:7222-25.
49. Nan F, Bzdega T, Pshenichkin S, et al. Dual function glutamate-related ligands: discovery of a novel, potent inhibitor of glutamate carboxypeptidase II possessing mGluR3 agonist activity. J Med Chem 2000;43:772-4.
50. Jackson PF, Tays KL, Maclin KM, et al. Design and pharmacological activity of phosphinic acid based NAALADase inhibitors. J Med Chem 2001;44:4170-5.
51. Kozikowski AP, Zhang J, Nan F, et al. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J Med Chem 2004;47:1729-38.
52. Barinka C, Byun Y, Dusich CL, et al. Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J Med Chem 2008;51:7737-43.
53. Choy CJ, Fulton MD, Davis AL, et al. Rationally designed sulfamides as glutamate carboxypeptidase II inhibitors. Chem Biol Drug Des. 2013;82:612-9.
54. Plechanovova A, Byun Y, Alquicer G, et al. Novel substratebased inhibitors of human glutamate carboxypeptidase II with enhanced lipophilicity. J Med Chem 2011;54:7535-46.
55. Barinka C, Rovenska M, Mlcochova P, et al. Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. J Med Chem 2007;250:3267-73.
56. Hlouchova K, Barinka C, Konvalinka J, et al. Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III. FEBS J. 2009;276:4448-62.
57. Wang H, Byun Y, Barinka C, et al. Bioisosterism of urea-based GCPII inhibitors: synthesis and structure-activity relationship studies. Bioorg Med Chem Lett 2010;20:392-7.
58. Lu XM, Tang Z, Liu W, et al., N-acetylaspartylglutamate protects against transient focal cerebral ischemia in rats. Eur J Pharmacol 2000;408:233-9.
59. Williams AJ, Lu XM, Slusher B, et al. Electroencephalogram analysis and neuroprotective profile of the N-acetylated-alphalinked acidic dipeptidase inhibitor, GPI5232, in normal and brain-injured rats. J Pharmacol Exp Ther 2001;299:48-57.
60. Bacich DJ, Wozniak KM, Lu XC, et al. Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury. J Neurochem 2005;95:314-23.
61. Cai Z, Lin S, Rhodes PG. Neuroprotective effects of Nacetylaspartylglutamate in a neonatal rat model of hypoxiaischemia. Eur J Pharmacol 2002;437:139-45.
62. Zhong C, Zhao X, Sarva J, et al. NAAG peptidase inhibitor reduces acute neuronal degeneration and astrocyte damage following lateral fluid percussion TBI in rats. J. Neurotrauma 2005;22:266-76.
63. Zhong C, Zhao X, Van LC, et al. NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat. J Neurochem 2006;97:1015-25.
64. Yamamoto T, Nozaki-Taguchi N, Sakashita T. Spinal Nacetylated- α-linked acidic dipeptidase (NAALADase) inhibition attenuates mechanical allodynia induced by paw carrageenan injection in the rat. Brain Res 2001;909:138-44.
65. Yamamoto T, Nozaki-Taguchi N, Sakashita Y, et al. Inhibition of spinal N-acetylated-α-linked acidic dipeptidase produces an antinociceptive effect in the rat formalin test. Neurosci 2001;102:473-9.
66. Chen SR, Wozniak KM, Slusher BS, et al. Effect of 2- (phosphonomethyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain. J Pharmacol Exp Ther 2002;300:662-7.
67. Carpenter KJ, Sen S,Matthews EA, et al. Effects of GCP-II inhibition on responses of dorsal horn neurones after inflammation and neuropathy: an electrophysiological study in the rat. Neuropeptides 2003;37:298-306.
68. Yamamoto T, Hirasawa S, Wroblewska B, et al. Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ 11, ZJ 17 and ZJ 43 in the rat formalin test and in the rat neuropathic pain model. Eur J Neurosci 2004;20: 483-94.
69. Zhang W., Slusher B., Murakawa Y., et al. GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats. J Neurol Sci 2002;194:21-8.
70. Bruno V, Wroblewska B, Wroblewski JT, et al. Neuroprotective activity of N-acetylaspartylglutamate in cultured cortical cells. Neuroscience 1998;85:751-7.
71. Thomas AG, Liu W, Olkowski JL, et al., Neuroprotection mediated by glutamate carboxypeptidase II (NAALADase) inhibition requires TGF-beta. Eur J Pharmacol 2001;430: 33-40.
72. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nature Rev Neurosci 2001;2:806-19.
73. Ghadge GD, Slusher BS, Bodner A, et al. Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci USA 2003;100:9554-9.
74. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-8.
75. Krystal JH, Anand A, Moghaddam B. Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia. Arch Gen Psychiatry 2002;59:663-4.
76. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998;281:1349-52.
77. Cartmell J, Monn JA, Schoepp DD. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetaminemotor behaviors in rats. J Pharmacol Exp Ther 1999;291:161-70.
78. Olszewski R, Buhkari N, Zhou J, et al. NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J Neurochem 2004;89:876-85.
79. Olszewski RT, Bzdega T, Neale JH. mGluR3 and not mGluR2 receptors mediate the efficacy of NAAG peptidase inhibitor in validated model of schizophrenia. Schizophr Res 2012;136:160-1.
80. Ferraguti F, Corti C, Valerio E, et al. Activated astrocytes in areas of kainate-induced neuronal injury upregulate the expression of the metabotropic glutamate receptors 2/3 and 5. Exp Brain Res 2001;137:1-11.
81. Aronica E, Gorter JA, Ijlst-Keizers H, et al. Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins. Eur J Neurosci 2003;17:2106-18.
82. Thomas AG, Liu W, Olkowski JL, et al. Neuroprotection mediated by glutamate carboxypeptidase II (NAALADase) inhibition requires TGF-beta. Eur J Pharmacol 2001;430:33-40.
83. Byrnes KR, Loane DJ, Faden AI. Metabotropic glutamate receptors as targets for multipotential treatment of neurological disorders. Neurotherapeutics 2009;6:94-107.
84. Urazaev AK, Buttram JG Jr, Deen JP, et al. Mechanisms for clearance of released N-acetylaspartylglutamate in crayfish nerve fibers: implications for axon-glia signaling. Neuroscience 2001;107:697-703.
85. Tsukamoto T, Wozniak KM, Slusher BS. Progress in the discovery and development of glutamate carboxypeptidase II inhibitors. Drug Discov Today 2007;12:767-76
86. Baslow MH. The astrocyte surface NAAG receptor and NAAG peptidase signaling complex as a therapeutic target. Drug News Perspect 2008;21:251-7.